📉 The Financial Deep Dive
Global Health Limited (Medanta) announced its Q3 FY26 financial results, showcasing robust top-line growth overshadowed by a significant drop in profitability due to exceptional items. Consolidated revenue for the quarter ended December 31, 2025, rose by an impressive 19.0% year-on-year to ₹112.10 crore from ₹94.34 crore in Q3 FY25.
However, consolidated Profit After Tax (PAT) experienced a sharp 33.5% decline, falling to ₹9.50 crore from ₹14.29 crore in the corresponding quarter last year. This substantial dip was primarily driven by exceptional items amounting to ₹36.60 crore in Q3 FY26, which the company attributed to the impact of new labour codes. In contrast, Q3 FY25 had a negative exceptional item of ₹15.99 crore related to stamp duty on a merger.
On a standalone basis, revenue grew from ₹81.24 crore in Q3 FY25 to ₹94.02 crore in Q3 FY26. Standalone PAT, however, saw a steeper fall of 39.1%, from ₹13.14 crore to ₹7.99 crore, also impacted by standalone exceptional items totalling ₹35.20 crore.
The nine-month period (ended December 31, 2025) offered a more stable picture for profitability. Consolidated revenue increased by 17.7% year-on-year to ₹325.11 crore from ₹276.11 crore. Consolidated PAT grew by a healthier 8.5% to ₹41.24 crore from ₹37.99 crore in the prior year's period. Standalone nine-month revenue was ₹274.87 crore (up from ₹240.13 crore YoY), and PAT saw a marginal increase of 0.8% to ₹37.21 crore from ₹36.81 crore YoY.
It is important to note that comparative periods have been restated due to the amalgamation of Medanta Holdings Private Limited with the Company, effective April 01, 2024.
🚩 Risks & Outlook
The immediate concern for investors is the significant impact of the exceptional items related to new labour codes. While revenue growth remains a positive indicator of operational strength, the substantial hit to PAT in Q3 FY26 due to these one-off costs necessitates close monitoring. The Street will watch for normalization of profitability in the subsequent quarters and management's strategy to mitigate any ongoing impact from these new labour regulations. Further clarity on the long-term implications of the labour code changes and their cost structure will be crucial for assessing future earnings quality. The approval of director re-appointments and new appointments indicates a stable governance framework moving forward.
The company also announced the appointment of Mr. Malik Mohd. Ashhab as 'Head-Diagnostic Services'. Additionally, the Board recommended the re-appointment of Dr. Ravi Gupta and Mr. Rajan Bharti Mittal as Independent Directors for a second term, subject to shareholder approval. Ms. Shonan Purie Trehan was proposed for appointment as a Non-Executive Non-Independent Director.